All In Biotech

Drug Trial Radar · NCT07918625

A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes.

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Aug 1, 2027

Study completion Aug 1, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of BGM1812 injection compared with placebo in reducing body weight in overweight or obese participants without diabetes after 26 weeks of treatment.

Conditions

  • Overweight or Obese Participants Without Diabetes

Interventions

  • BGM1812 injection / plcaeboDrug

    Once weekly or once every two weeks, administered continuously for 24 weeks.

  • BGM1812 injection / plcaeboDrug

    Once weekly or once every two weeks, administered continuously for 24 weeks.

  • BGM1812 injection / plcaeboDrug

    Once weekly or once every two weeks, administered continuously for 24 weeks.

  • BGM1812 injection / plcaeboDrug

    Once weekly or once every two weeks, administered continuously for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body WeightTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Soochow University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.